Abstract
Corneal angiogenesis and lymphangiogenesis are induced by vascular endothelial growth factors (VEGFs) signaling through its receptors VEGFR-1, -2, and -3. Endostatin is a peptide antagonist of these receptors that causes inhibition of bFGF-induced corneal angiogenesis and lymphangiogenesis. Here we show that binding of VEGF-C and endostatin to recombinant VEGFR-3 is competitive. Alignments of the primary amino acid sequences of VEGF-C and the C-terminal endostatin peptide (mEP: LEQKAASCHNSYIVLCIENSFMTSFSK) identified two conserved cysteine residues separated by seven amino acids. Peptides of VEGF-C and mEP containing these conserved residues bound toVEGFR-3. However, substitution of alanine for either of the cysteines in the mEP peptide perturbed the secondary structure, and this mutated peptide was unable to bind to VEGFR-3. Analysis by surface plasmon resonance demonstrated that the binding of the mEP peptide for recombinant VEGFR-3 had a Ka of 1.41x107M-1s-1, Kd of 0.6718 s-1, and a KD of 4.78x10-8M. Characterization of the mechanism of endostatin binding to VEGFR-3 may lead to the development of novel therapies for lymphangiogenesis-related disorders, such as transplant rejection, lymphedema, and cancer metastasis.
Keywords: Endostatin, lymphangiogenesis, peptide fragment, surface plasmon resonance, VEGF, VEGFR
Protein & Peptide Letters
Title:Characterization of the Interaction Between Endostatin Short Peptide and VEGF Receptor 3
Volume: 19 Issue: 9
Author(s): Kyu-Yeon Han, Dimitri T. Azar, Abdellah Sabri, Hyun Lee, Sandeep Jain, Bao-Shiang Lee and Jin-Hong Chang
Affiliation:
Keywords: Endostatin, lymphangiogenesis, peptide fragment, surface plasmon resonance, VEGF, VEGFR
Abstract: Corneal angiogenesis and lymphangiogenesis are induced by vascular endothelial growth factors (VEGFs) signaling through its receptors VEGFR-1, -2, and -3. Endostatin is a peptide antagonist of these receptors that causes inhibition of bFGF-induced corneal angiogenesis and lymphangiogenesis. Here we show that binding of VEGF-C and endostatin to recombinant VEGFR-3 is competitive. Alignments of the primary amino acid sequences of VEGF-C and the C-terminal endostatin peptide (mEP: LEQKAASCHNSYIVLCIENSFMTSFSK) identified two conserved cysteine residues separated by seven amino acids. Peptides of VEGF-C and mEP containing these conserved residues bound toVEGFR-3. However, substitution of alanine for either of the cysteines in the mEP peptide perturbed the secondary structure, and this mutated peptide was unable to bind to VEGFR-3. Analysis by surface plasmon resonance demonstrated that the binding of the mEP peptide for recombinant VEGFR-3 had a Ka of 1.41x107M-1s-1, Kd of 0.6718 s-1, and a KD of 4.78x10-8M. Characterization of the mechanism of endostatin binding to VEGFR-3 may lead to the development of novel therapies for lymphangiogenesis-related disorders, such as transplant rejection, lymphedema, and cancer metastasis.
Export Options
About this article
Cite this article as:
Han Kyu-Yeon, T. Azar Dimitri, Sabri Abdellah, Lee Hyun, Jain Sandeep, Lee Bao-Shiang and Chang Jin-Hong, Characterization of the Interaction Between Endostatin Short Peptide and VEGF Receptor 3, Protein & Peptide Letters 2012; 19 (9) . https://dx.doi.org/10.2174/092986612802084465
DOI https://dx.doi.org/10.2174/092986612802084465 |
Print ISSN 0929-8665 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5305 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
MicroRNAs in Arterial Hypertension
Current Topics in Medicinal Chemistry Semicarbazide-Sensitive Amine Oxidase/Vascular Adhesion Protein 1: Recent Developments Concerning Substrates and Inhibitors of a Promising Therapeutic Target
Current Medicinal Chemistry To Enhance or to Inhibit Integrin Function in Angiogenesis, that is the Question
Current Angiogenesis (Discontinued) Applications and Case Studies of the Next-Generation Sequencing Technologies in Food, Nutrition and Agriculture
Recent Patents on Food, Nutrition & Agriculture Evaluation of Ocular Irritation and Bioavailability of Voriconazole Loaded Microemulsion
Current Drug Delivery Emerging Potential of Natural Products as an Alternative Strategy to Pharmacological Agents Used Against Metabolic Disorders
Current Drug Metabolism Advances in the Management of Brain Tumors in Infants
Current Cancer Therapy Reviews Stem Cell Therapies for the Lysosomal Storage Diseases – the Quintessential Neurodegenerative Diseases
Current Stem Cell Research & Therapy Cell-and Gene-based Therapeutic Approaches for Neurological Deficits in Mucopolysaccharidoses
Current Pharmaceutical Biotechnology Virulence Mechanisms Displayed by Salmonella to Impair Dendritic Cell Function
Current Medicinal Chemistry Self-care improvement after a pharmaceutical intervention in elderly type 2 diabetic patients
Current Diabetes Reviews Living Life to the Fullest: Early Integration of Palliative Care into the Lives of Children with Chronic Complex Conditions
Current Pediatric Reviews Diabetes Mellitus: Channeling Care through Cellular Discovery
Current Neurovascular Research Changes in the Expression of the Alzheimers Disease-Associated Presenilin Gene in Drosophila Heart Leads to Cardiac Dysfunction
Current Alzheimer Research Pharmacological Aspects of the Enzastaurin-Pemetrexed Combination in Non-Small Cell Lung Cancer (NSCLC)
Current Drug Targets The Role of Orexin System in Antipsychotics Induced Weight Gain
Current Psychiatry Reviews Targeting Chk2 Kinase: Molecular Interaction Maps and Therapeutic Rationale
Current Pharmaceutical Design Green Tea Catechins and Cardiovascular Health: An Update
Current Medicinal Chemistry LC/MS/MS Profiling of Tissue Oxysterols and its Application in Dextran Sodium Sulphate Induced Mouse Colitis Models
Current Topics in Medicinal Chemistry Antiproliferative Strategies for the Treatment of Vascular Proliferative Disease
Current Vascular Pharmacology